Barclays’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
– Sell
-6,533
Closed -$572K – 7228
2018
Q2
$572K Buy
+6,533
New +$1.15M ﹤0.01% 3815

Other funds holding GYRE

Barclays's GYRE Position: Q3 2026 in Review

Barclays increased its Gyre Therapeutics (GYRE) stake by 922% in Q3 2026, buying an estimated $198K and bringing the position to 32,975 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3851.

Barclays first reported a position in GYRE in Q2 2013 and has held it in 42 quarters since. The position peaked at $454K in Q2 2018. 58 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.

  • Barclays held 32,975 shares of Gyre Therapeutics worth $242K as of Q3 2026.
  • Barclays bought 29,747 Gyre Therapeutics shares in Q3 2026, an estimated $198K.
  • Gyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3851 holding.
  • Barclays first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Barclays's Gyre Therapeutics position peaked at $454K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.